Enphase Energy Inc vs Natera Inc. Common Stock — how do they compare? Enphase Energy Inc trades at $29 (market cap $4.23B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 13.5× Enphase Energy Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Natera Inc. Common Stock for 0 Days on average.
| ENPH | NTRA | |
|---|---|---|
Market Cap | $4.23B | $57.03B |
Volume | 4,755,897 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $72.33 | $425.64 |
52-Week Low | $26.12 | $179.42 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $29.35, down 6.8% in the last session, reflecting recent volatility amid broader solar sector pressures. The stock shows a bearish technical signal with key support at $29. Valuation ratios like a P/E of 31.71 and P/S of 3.22 suggest a premium, while recent quarters saw mixed earnings with two misses. Positive developments include utility approvals for its IQ Meter Collar and advancements in solid-state transformer technology for AI data centers.
The outlook is cautious; while analyst consensus targets $43.18 implying upside, high borrowing costs and competitive risks weigh on solar stocks. Revenue declined from 2023's $2.3B to $1.47B in 2025, though net margins improved. Investors should balance growth potential in energy tech against execution risks and market sentiment shifts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →